Maker Of ALS Drug Relyvrio Considers Pulling Product

Amylyx Pharmaceuticals, the maker of Relyvrio, a drug for amyotrophic lateral sclerosis (ALS), has announced that its therapy failed to demonstrate efficacy in a large follow-up study, reports Matthew Perrone for the Associated Press (AP).

Amylyx Pharmaceuticals expressed surprise and disappointment at the results and announced plans to discuss the future of Relyvrio with patients and the FDA. I Photo: Amylyx Pharmaceuticals

Despite this setback, the company has not committed to withdrawing the drug from the US market. The Food and Drug Administration (FDA) approved Relyvrio in September 2022 following advocacy efforts by ALS patients.

However, the latest study showed that the drug did not slow the progression of the disease compared to a placebo.

Additionally, it failed to show improvement in secondary measures such as muscle strength.

Amylyx Pharmaceuticals expressed surprise and disappointment at the results and announced plans to discuss the future of Relyvrio with patients and the FDA. The company may consider voluntarily withdrawing the drug from the market.

ALS is a devastating disease that causes the progressive degeneration of nerve cells, leading to severe muscle weakness and paralysis.

WEEKLY FEATURE : Jose Mari Chan And The Christmas Anthem